# Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

> **NCT02811783** · PHASE3 · TERMINATED · sponsor: **Elorac, Inc.** · enrollment: 59 (actual)

## Conditions studied

- Mycosis Fungoides
- Lymphoma, T-Cell, Cutaneous
- Sézary Syndrome

## Interventions

- **DRUG:** Naloxone Hydrochloride Lotion, 0.5%
- **DRUG:** Placebo Lotion

## Key facts

- **NCT ID:** NCT02811783
- **Lead sponsor:** Elorac, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01
- **Primary completion:** 2022-09
- **Final completion:** 2022-09
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2022-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02811783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02811783, "Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02811783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*